9-Nonylpurine (BioDeep_00000185403)
human metabolite blood metabolite
代谢物信息卡片
9-nonyl-9H-purine
化学式: C14H22N4 (246.1844372)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCN1C=NC2=CN=CN=C12
InChI: InChI=1S/C14H22N4/c1-2-3-4-5-6-7-8-9-18-12-17-13-10-15-11-16-14(13)18/h10-12H,2-9H2,1H3
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- X-X Liu, R-J Liu, L Ding, Y-F Lin, N-Y Huang, H-F Xiao, Y Huang, J Yang, S-L Wang. Pharmacokinetics of febuxostat in healthy Chinese volunteers.
Arzneimittel-Forschung.
2012 Oct; 62(10):463-9. doi:
10.1055/s-0032-1321847. [PMID: 22956350] - Max Tsai, Jing-tao Wu, Lhanoo Gunawardhana, Himanshu Naik. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
International journal of clinical pharmacology and therapeutics.
2012 May; 50(5):331-7. doi:
10.5414/cp201648. [PMID: 22541837] - P Richette. [Gout: an overview of available urate lowering therapies].
Annales pharmaceutiques francaises.
2012 May; 70(3):133-8. doi:
10.1016/j.pharma.2012.02.003. [PMID: 22655581] - Robert L Jackson, Barbara Hunt, Patricia A MacDonald. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
BMC geriatrics.
2012 Mar; 12(?):11. doi:
10.1186/1471-2318-12-11. [PMID: 22436129] - Manisha Bisht, S S Bist. Febuxostat: a novel agent for management of hyperuricemia in gout.
Indian journal of pharmaceutical sciences.
2011 Nov; 73(6):597-600. doi:
10.4103/0250-474x.100231. [PMID: 23112391] - David S Goldfarb. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.
Clinical journal of the American Society of Nephrology : CJASN.
2011 Aug; 6(8):2093-7. doi:
10.2215/cjn.00320111. [PMID: 21757641] - Charnelda L Gray, Nafesa E Walters-Smith. Febuxostat for treatment of chronic gout.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2011 Mar; 68(5):389-98. doi:
10.2146/ajhp100394. [PMID: 21330679] - Brian A Grabowski, Reza Khosravan, Laurent Vernillet, Darcy J Mulford. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Journal of clinical pharmacology.
2011 Feb; 51(2):189-201. doi:
10.1177/0091270010365549. [PMID: 20354234] - Brian Grabowski, Reza Khosravan, Jing-Tao Wu, Laurent Vernillet, Christopher Lademacher. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
British journal of clinical pharmacology.
2010 Jul; 70(1):57-64. doi:
10.1111/j.1365-2125.2010.03667.x. [PMID: 20642548] - Angelo L Gaffo, Kenneth G Saag. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.
Core evidence.
2010 Jun; 4(?):25-36. doi:
10.2147/ce.s5999. [PMID: 20694062] - Lada Beara-Lasic, Michael H Pillinger, David S Goldfarb. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.
International journal of nephrology and renovascular disease.
2010; 3(?):1-10. doi:
10.2147/ijnrd.s5563. [PMID: 21694922] - Michael A Becker, H Ralph Schumacher, Luis R Espinoza, Alvin F Wells, Patricia MacDonald, Eric Lloyd, Christopher Lademacher. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Arthritis research & therapy.
2010; 12(2):R63. doi:
10.1186/ar2978. [PMID: 20370912] - Maria Majdan, Olga Borys. [Gout and comorbidities associated with hyperuricemia].
Annales Academiae Medicae Stetinensis.
2010; 56 Suppl 1(?):34-9. doi:
NULL. [PMID: 21365938] - Jasvinder A Singh. Advances in gout: some answers, more questions.
Arthritis research & therapy.
2010; 12(5):136. doi:
10.1186/ar3110. [PMID: 20959031] - Michael E Ernst, Michelle A Fravel. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Clinical therapeutics.
2009 Nov; 31(11):2503-18. doi:
10.1016/j.clinthera.2009.11.033. [PMID: 20109996] - Galia Lazova, Petranka Yonova. Changes in the leaf polypeptide patterns of wheat flag leaves spraying with non-purine cytokinins.
Acta biologica Hungarica.
2008 Dec; 59(4):501-5. doi:
10.1556/abiol.59.2008.4.10. [PMID: 19133505] - Miao Hu, Brian Tomlinson. Febuxostat in the management of hyperuricemia and chronic gout: a review.
Therapeutics and clinical risk management.
2008 Dec; 4(6):1209-20. doi:
10.2147/tcrm.s3310. [PMID: 19337428] - Reza Khosravan, Michael J Kukulka, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Journal of clinical pharmacology.
2008 Sep; 48(9):1014-24. doi:
10.1177/0091270008322035. [PMID: 18635756] - M Mukoyoshi, S Nishimura, S Hoshide, S Umeda, M Kanou, K Taniguchi, H Muroga. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
Xenobiotica; the fate of foreign compounds in biological systems.
2008 May; 38(5):496-510. doi:
10.1080/00498250801956350. [PMID: 18421623] - Laura G Sánchez-Lozada, Edilia Tapia, Virgilia Soto, Carmen Avila-Casado, Martha Franco, Lin Zhao, Richard J Johnson. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2008 Apr; 23(4):1179-85. doi:
10.1093/ndt/gfm783. [PMID: 18048425] - Laura G Sánchez-Lozada, Edilia Tapia, Pablo Bautista-García, Virgilia Soto, Carmen Avila-Casado, Iliana P Vega-Campos, Takahiko Nakagawa, Lin Zhao, Martha Franco, Richard J Johnson. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
American journal of physiology. Renal physiology.
2008 Apr; 294(4):F710-8. doi:
10.1152/ajprenal.00454.2007. [PMID: 18216151] - Philip I Hair, Paul L McCormack, Gillian M Keating. Febuxostat.
Drugs.
2008; 68(13):1865-74. doi:
10.2165/00003495-200868130-00006. [PMID: 18729537] - Laura G Sánchez-Lozada, Edilia Tapia, Virgilia Soto, Carmen Avila-Casado, Martha Franco, Jerry L Wessale, Lin Zhao, Richard J Johnson. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Nephron. Physiology.
2008; 108(4):p69-78. doi:
10.1159/000127837. [PMID: 18434753] - Alexander So. Developments in the scientific and clinical understanding of gout.
Arthritis research & therapy.
2008; 10(5):221. doi:
10.1186/ar2509. [PMID: 18947374] - Lisa Cammalleri, Mariano Malaguarnera. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
International journal of medical sciences.
2007 Mar; 4(2):83-93. doi:
10.7150/ijms.4.83. [PMID: 17396159] - George Nuki, Peter A Simkin. A concise history of gout and hyperuricemia and their treatment.
Arthritis research & therapy.
2006; 8 Suppl 1(?):S1. doi:
10.1186/ar1906. [PMID: 16820040] - Reza Khosravan, Brian A Grabowski, Michael D Mayer, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Journal of clinical pharmacology.
2006 Jan; 46(1):88-102. doi:
10.1177/0091270005282634. [PMID: 16397288] - Robert Terkeltaub, David A Bushinsky, Michael A Becker. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Arthritis research & therapy.
2006; 8 Suppl 1(?):S4. doi:
10.1186/ar1909. [PMID: 16820043] - Reza Khosravan, Brian A Grabowski, Jing-Tao Wu, Nancy Joseph-Ridge, Laurent Vernillet. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Clinical pharmacokinetics.
2006; 45(8):821-41. doi:
10.2165/00003088-200645080-00005. [PMID: 16884320] - Michael A Becker, H Ralph Schumacher, Robert L Wortmann, Patricia A MacDonald, Denise Eustace, William A Palo, Janet Streit, Nancy Joseph-Ridge. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
The New England journal of medicine.
2005 Dec; 353(23):2450-61. doi:
10.1056/nejmoa050373. [PMID: 16339094] - H Ralph Schumacher. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Expert opinion on investigational drugs.
2005 Jul; 14(7):893-903. doi:
10.1517/13543784.14.7.893. [PMID: 16022578] - Michael A Becker, H Ralph Schumacher, Robert L Wortmann, Patricia A MacDonald, William A Palo, Denise Eustace, Laurent Vernillet, Nancy Joseph-Ridge. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Arthritis and rheumatism.
2005 Mar; 52(3):916-23. doi:
10.1002/art.20935. [PMID: 15751090] - Michael D Mayer, Reza Khosravan, Laurent Vernillet, Jing-Tao Wu, Nancy Joseph-Ridge, Darcy J Mulford. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
American journal of therapeutics.
2005 Jan; 12(1):22-34. doi:
10.1097/00045391-200501000-00005. [PMID: 15662289] - Atsushi Fukunari, Ken Okamoto, Takeshi Nishino, Bryan T Eger, Emil F Pai, Miho Kamezawa, Ichimaro Yamada, Norihisa Kato. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
The Journal of pharmacology and experimental therapeutics.
2004 Nov; 311(2):519-28. doi:
10.1124/jpet.104.070433. [PMID: 15190124] - M A Becker, J Kisicki, R Khosravan, J Wu, D Mulford, B Hunt, P MacDonald, N Joseph-Ridge. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Nucleosides, nucleotides & nucleic acids.
2004 Oct; 23(8-9):1111-6. doi:
10.1081/ncn-200027372. [PMID: 15571211]